Morten heads regulatory affairs at Vantia Therapeutics
Vantia Therapeutics, a developer of novel small molecule drugs, has appointed Rachel Morten as head of regulatory affairs.
Morten has more than 24 years" experience in global regulatory affairs and product development in the pharmaceutical and animal health industries.
Most recently an independent regulatory affairs consultant, she has also served as senior director, group head regulatory affairs for Averion International. Prior to this, she founded ChapelPharma, a regulatory consultancy that was acquired by Hesperion in 2004.